Trial · NCT00395044
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 | Gabapentin | -966.00 | Standard Deviation 1175.25 | ng/ml | |
| Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 | Placebo | -532.81 | Standard Deviation 422.15 | ng/ml | |
| Change From Week 0 in Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at Week 12 | Gabapentin | 1.42 | Standard Deviation 1.13 | units on a scale | |
| Change From Week 0 in Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at Week 12 | Placebo | 2.12 | Standard Deviation 1.50 | units on a scale | |
| Change in Sleep Quality on the Pittsburgh Sleep Quality Index (PSQI) at Week 12 | Gabapentin | -4.27 | Standard Deviation 3.07 | units on a scale | |
| Change in Sleep Quality on the Pittsburgh Sleep Quality Index (PSQI) at Week 12 | Placebo | -1.72 | Standard Deviation 2.80 | units on a scale | |
| Change From Week 0 in Mood on the Beck Depression Inventory (BDI-II) at Week 12 | Gabapentin | 3.71 | Standard Deviation 1.98 | units on a scale | |
| Change From Week 0 in Mood on the Beck Depression Inventory (BDI-II) at Week 12 | Placebo | 5.22 | Standard Deviation 2.36 | units on a scale | |
| Change From Week 0 in Craving on the Marijuana Withdrawal Checklist Marijuana Craving Question at Week 12 | Gabapentin | -1.55 | Standard Deviation .64 | units on a scale | |
| Change From Week 0 in Craving on the Marijuana Withdrawal Checklist Marijuana Craving Question at Week 12 | Placebo | -1.46 | Standard Deviation .77 | units on a scale | |
| Change From Week 0 in Cannabis-related Problems on the Marijuana Problem Scale (MPS) at Week 12 | Gabapentin | -3.40 | Standard Deviation 2.07 | units on a scale | |
| Change From Week 0 in Cannabis-related Problems on the Marijuana Problem Scale (MPS) at Week 12 | Placebo | -4.90 | Standard Deviation 7.09 | units on a scale | |
| Change From Baseline in Cognitive Functioning Using the Delis-Kaplan Executive Function System (D-KEFS) at Week 4 | Gabapentin | .28 | Standard Deviation .50 | scores on a scale | |
| Change From Baseline in Cognitive Functioning Using the Delis-Kaplan Executive Function System (D-KEFS) at Week 4 | Placebo | -.20 | Standard Deviation .31 | scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00395044/results